The inhibitory effect of *Zingiber corallinum* Hance essential oil on drug-resistant bacteria and evaluation of its acute toxicity

Ce Yang¹₂*, Lin-Lin Zhou¹₂*, Hai-Yan Wang¹, Su-Na Huang¹, Qing Liu¹, Shi-Lin Hu², Ting Rong Li², Yan-Bing Chen², Jian-Xin Jiang¹

¹ These authors contributed equally to this paper

¹ State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Surgery Research, Daping Hospital, 3rd Military Medical University, Changjiang Zhilu, Daping, Chongqing, P. R. China
² Chongqing Research Institute of Daily-used Chemical Industry, Chongqing, P. R. China

**Summary**

**Background:** The excessive and irregular use of antibiotics could result in the generation and diffusion of drug-resistant bacteria. The aim of this study was to investigate the inhibitory effect of *Zingiber corallinum* Hance essential oil (ZCHO) on drug-resistant bacteria, especially on drug-resistant *Acinetobacter baumannii*.

**Material/Methods:** Susceptibility testing was used to evaluate the effect of ZCHO on growth inhibition of drug-resistant bacteria by paper disk method. Mice orally administered with ZCHO were used to observe acute toxicity and to determine median lethal dose (LD₅₀) of ZCHO. Broth dilution method was used to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of ZCHO on drug-resistant *Acinetobacter baumannii*.

**Results:** ZCHO exhibited an obvious inhibitory effect not only on gram-negative drug-resistant bacteria including *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae* and *Acinetobacter baumannii*, but also on gram-positive drug-resistant bacteria including *Staphylococcus aureus*, *Staphylococcus epidermidis* and *Staphylococcus haemolyticus*. The ZCHO containing 79% terpinen-4-ol revealed better bacteriostatic effect than ZCHO with 34% terpinen-4-ol. The LD₅₀ of ZCHO was 1790.427 mg/kg. The MIC and MBC of ZCHO on drug-resistant *Acinetobacter baumannii* were 1457.81 mg/L.

**Conclusions:** ZCHO has obvious bacteriostasis and bactericidal effects, especially against drug-resistant *Acinetobacter baumannii*. Therefore, ZCHO is a promising natural bioactive component with antibacterial effect and satisfactory safety due to its low toxicity.

**key words:** *Zingiber corallinum* Hance essential oil • Terpinen-4-ol • LD₅₀ • drug-resistant bacteria
Background

Antibiotics have played a vital role in controlling infectious diseases. Unfortunately, the excessive and irregular use of antibiotics can result in the generation and diffusion of drug-resistant bacteria [1,2]. Increasing difficulties in clinical therapy for infected patients have been observed due to the diminishing therapeutic effect of antibiotics. Currently, drug resistance to bacteria has become an important research focus. Previous studies confirmed that natural products not only provided extensive antibacterial activities, but also avoided the generation of drug-resistant bacteria [3,4]. Therefore, natural product drugs have received tremendous attention.

Zingiber corallinum Hance, also referred to as Yin Jiang or Jab bangx hnaib diel, is a Chinese herbal plant in the ginger family and ginger group (Figure 1). It has anti-inflammatory, detoxifying and anti-bacterial functions [5,6]. As a traditional perennial herb native to Yunnan, Guangxi, Guangdong and Guizhou areas, Zingiber corallinum Hance has been used for catarral rhinitis, cough, lumbago and diarrhea with satisfactory therapeutic effects [7]. The bioactive components in Zingiber corallinum Hance are aetherolea and coral ginger essential oil, and Zingiber corallinum Hance essential oil (ZCHO) that has obvious antibacterial activity [8,9]. Through supercritical carbon dioxide extraction, the essential oil was isolated from Zingiber corallinum Hance and identified by gas chromatography-mass spectroscopy [10]. The major bioactive components among 60 compounds that were identified are terpinen-4-ol, sabinene, β-bisabolene and α-terpinene. ZCHO has attracted extensive attention due to its antibiosis property. Previous reports described its inhibitory effect on fungi and some non-drug-resistant pathogenic bacteria [11]; however, there have been few reports on its role in controlling drug-resistant pathogenic bacteria.

Acinetobacter baumannii is an important pathogen for hospital onset of infections (HOI) [12,13]. Intensive care unit (ICU) patients are at increased risk of infection with multi-drug-resistant A. baumannii [14–16]. In the last decade, non-fermentable sugar gram-negative bacilli have become a common nosocomial infection. Due to extensive use of broad-spectrum antibiotics, infection with multi-drug-resistant Acinetobacter baumannii has significantly increased. Recently, the infection of multidrug-resistant A. baumannii has resulted in an explosive increase in prevalence in many places around the world, including Europe, North America, Argentina, Brazil, Taiwan, Hong Kong, Japan and Korea [17–22]. Therefore, infection with this bacterium could easily become epidemic in some locations due to the shortage of effective antibiotics.

Based on previous observations, we chose to further explore the inhibitory effect of ZCHO on common drug-resistant bacteria, especially on drug-resistant A. baumannii. The aim of the present study was to: (1) To investigate the bacteriostasis effect of ZCHO on common drug-resistant pathogen bacteria during clinical treatments; (2) To evaluate the acute toxicity of ZCHO for ensuring its safety in clinical practice; (3) To further examine its bacteriostasis and bactericidal effects on drug-resistant A. baumannii, an important nosocomial pathogen. We first used the paper disk method to investigate the bacteriostatic effect of ZCHO on common drug-resistant bacteria, as well as to explore the major components of ZCHO for bacteriostasis effect. We also examined the acute toxicity of ZCHO by using modified Karber’s method to determine median lethal dose (LD50) in mice. Moreover, the broth dilution method was conducted to determine minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of ZCHO on drug-resistant A. baumannii. Therefore, this study will provide new experimental evidence to facilitate the development of effective antibacterial drugs for controlling common drug-resistant bacteria.

Material and Methods

Bacterial isolation

The clinical isolates from Daping Hospital, the Third Military Medical University, P. R. China, were used to examine the resistance to antibiotics (Table 1). The isolates included 3 gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus) and 5 gram-negative bacteria (Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii). These bacteria were examined under a microscope and identified through physiological and biochemical methods [23,24]. The identified bacteria were stored at –80°C for future experiments.

ZCHO

ZCHO was provided by the Chongqing Institute of Daily-used Chemical Industry, P. R. China. All batches complied with the International Organization for Standardization (ISO) 9001. The major bioactive component in ZCHO was determined by gas chromatography-mass spectrometry at Chongqing Institute of Daily-used Chemical Industry (Table 2). Two kinds of ZCHO are ZCHO standard essential oil with 34% terpinen-4-ol and concentrated ZCHO essential oil with 79% terpinen-4-ol.
Preparation of bacterial fluid

According to NCCLS guidelines [25], the isolated bacteria were inoculated in Luria-Bertani broth (LB; Oxoid, Basingstoke, UK) and grown at 37°C overnight. The grown bacteria was adjusted to a 0.5 McFarland standard in broth according to turbidity on the turbidimeter (Marcy-I’Etoile, France), and a further dilution was made by adding 100 µL of bacteria in glass flasks containing 10 mL of Mueller Hinton (MH) broth. The final concentration of bacteria in the flasks was 5×10^5 CFU/mL. The bacterial isolates were cultured at 37°C in glass flasks with shaking of 150 revolutions per minute (rpm) for 240 min.

Experimental animals and grouping

Healthy C57 adult mice with body weight of 18–22 g were provided by the experimental animal center of Daping Hospital (SCXK(yu)2007017), at the Third Military Medical University. The mice were kept in a specific pathogen-free room with free access to standard laboratory food and water under the condition of controlled temperature, humidity and lighting (12-hour light-dark cycles). The mice were randomly divided into 9 groups, with 10 mice in each group, designated as 1 negative control group and 8 experimental groups treated with ZCHO at various concentrations.

---

Table 1. The types of bacteria with non-susceptive antibiotic spectrum.

| Bacteria type           | Gram type | Non-susceptive antibiotics                                                                 |
|-------------------------|-----------|------------------------------------------------------------------------------------------|
| Escherichia coli        | G–        | penicillins • cephalosporins • aztreonam                                                  |
| Enterobacter cloacae    | G–        | amikacin • ampicillin • sulbactam • aztreonam • ceftriaxone • ciprofloxacin • gentamicin •  |
|                         |           | levofloxacin • furantoin • piperacillin • tenebrimycin                                      |
| Klebsiella pneumoniae   | G–        | penicillins • cephalosporins • aztreonam                                                  |
| Pseudomonas aeruginosa  | G–        | amikacin • cefotaxim • ceftizoxime • ceftriaxone • ciprofloxacin • gentamicin • levofloxacin • |
|                         |           | piperacil • ambramycin • bactrim • ticarcellin • tobramycin                                |
| Acinetobacter baumannii | G–        | aztreonam • cephalosporins • gentamyce • piperacil • ambramyce • bactrim • ticarcellin •  |
|                         |           | tobramycin                                                                                 |
| Staphylococcus aureus   | G+        | penicillins • βlactam/β-lactam inhibitor complex • cephalosporins • carabapenem antibiotics |
| Staphylococcus epidermidis | G+   | penicillins • βlactam/β-lactam inhibitor complex • cephalosporins • carabapenem antibiotics |
| Staphylococcus haemolyticus | G+   | penicillins • βlactam/β-lactam inhibitor complex • cephalosporins • carabapenem antibiotics |

Table 2. The major constituents of Zingiber corallinum Hance essential oil.

| Chemical name         | Molecular formula | Peak area(%) | Structure formula |
|-----------------------|-------------------|--------------|------------------|
| terpinen-4-ol         | C_{10}H_{16}O     | >30.00       |                  |
| β-bisabolene          | C_{15}H_{24}      | 21.00        |                  |
| sabinene              | C_{10}H_{16}      | 10.55        |                  |
| α-terpineol           | C_{10}H_{16}O     | 2.88         |                  |
| α-terpinene           | C_{18}H_{16}      | 0.71         |                  |
| β-Sesquiphellandrene  | C_{15}H_{24}      | 0.57         |                  |
| zingiberene           | C_{15}H_{24}      | 0.19         |                  |
Table 3. The diameters of bacteriostasis rings after Zingiber corallinum Hance essential oil treatment (mm, \(\bar{x}\pm SD\)).

| Group  | Gram-negative drug-resistant bacteria | Gram-positive drug-resistant bacteria |
|--------|--------------------------------------|---------------------------------------|
|        | Escherichia coli | Enterobacter cloacae | Klebsiella pneumoniae | Acinetobacter baumannii | Pseudomonas aeruginosa | Staphylococcus aureus | Staphylococcus epidermidis | Staphylococcus haemolyticus |
| 1      | 31.00±10.77** | 32.50±9.38*** | 24.71±6.18** | 23.13±4.26** | 7.30±0.67** | 19.43±4.08* | 15.00±3.74* | 13.00±2.19* |
| 2      | 14.40±3.85** | 11.92±2.15** | 12.64±2.63** | 14.00±4.47** | 0 | 10.86±5.76 | 10.25±0.96 | 4.83±3.78** |
| 3      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4      | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

* \(P<0.05\) vs. the group 2; ** \(P<0.01\) vs. the group 3; \# \(P<0.05\); ## \(P<0.01\) vs. the group 4.

All experiments were carried out according to the guidelines from the Third Military Medical University Animal Research Committee. These guidelines include minimizing the number of animals for experiments and minimizing the suffering for animals.

Concentration screening

The optimal concentration of ZCHO containing 79% terpinen-4-ol was screened from the range of 5–40%. The dilution ratio of concentration between adjacent groups was designed to be 0.769 according to modified Karber’s method [26]. Polyoxyethylene sorbitan monolaurate (Tween-20) was added to all ZCHO dilutions in a final concentration of 1% (v/v) for enhancing the solubility of ZCHO. The stock ZCHO was diluted to a final concentration (v/v) of 6.5%, 8.4%, 11.0%, 14.3%, 18.6%, 24.1%, 31.4% and 40.0% using physiological saline.

Susceptibility test using paper disk

Susceptibility was determined by use of standard paper disks including ampicillin paper disk for gram-negative bacteria control, penicillin paper disk for gram-positive bacteria control and blank paper disk (Oxoid; Basingstoke, UK). The bacteria fluid was dipped with sterile swab paper to spread on Mueller Hinton agar (MHA) plates in duplicate. After drying for 5 minutes, the paper disks were tightly pasted on the surface of MHA plates. The distance between the centers of paper disks was more than 24 mm. The distance between the center of paper disks and the inner margin of plates was more than 15 mm. Finally, the plates with various concentrations were incubated at 35°C for 24 h.

Acute toxicity test

All mice were administered with ZCHO (0.01 ml/g) at various concentrations by oral gavage to determine median lethal dose (LD50) [27]. During the 2-week observation period, the dead mice were subjected to immediate biopsy to analyze the acute toxicity of ZCHO. The tissues of lungs, livers, intestine and kidneys were fixed overnight in 4% paraformaldehyde solution. The samples were progressively dehydrated with ethanol and dimethylbenzene and then embedded with paraffin. Hematoxylin and eosin (HE) staining was used to examine histopathological changes in these tissues.

MIC and MBC determination

MICs were determined using serial dilution methods as previously described [28]. Tween-20 at a final concentration of 1% (v/v) was added in all dilutions to enhance the solubility of ZCHO. One milliliter of A. baumannii fluid was inoculated in each group. ZCHO was added to culture flasks at final concentrations of 10%, 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.156% and 0.078% (v/v). One milliliter of A. baumannii fluid and 1 ml of LB were added to the positive control flask. In the blank control flask, 1 ml of A. baumannii fluid and 1 ml of Tween-80 were added. After mixing thoroughly, these flasks were shaken at 35°C, 150 rpm for 16 h. Since the tested samples with milliliter belong to emulsion. The dilution of multiple proportions still could not discriminate the growth of bacteria. Hence, the other inoculation of varying concentrations of cultures was used. Plates were incubated at 37°C and MICs were determined at 24 h. The MICs were defined as the lowest concentration of ZCHO that resulted in the inhibition of visible growth (colonies on a plate) under standard conditions.

MBCs were determined in duplicate using 100 \(\mu\)l of the above-mentioned A. baumannii fluid and MHA plates according to National Committee for Clinical Laboratory Standards (NCCLS) guidelines [25]. The plates containing ZCHO at various concentrations were incubated at 37°C and MBCs were determined at 24 h. The MBCs were the lowest concentration of ZCHO that could kill 99.9% of the original inoculum in a given time. The number of colonies should be less than 5. All broth dilution tests were performed at least twice.

Statistical analysis

The data are presented as mean ± standard deviation (SD). Student’s t test was used to calculate statistical difference between groups. The reforming Karber’s method was used to calculate the LD50 and 95% confidence interval. The statistical level was set at 95%. All statistical calculations were performed using the SPSS13.0 software for Windows.

RESULTS

ZCHO inhibits the growth of drug-resistant bacteria

ZCHO resulted in an obvious bacteriostasis ring for gram-negative drug-resistant bacteria such as E. coli, E. cloacae, K. pneumoniae and A. baumannii, as well as gram-positive drug-resistant bacteria including S. aureus, S. epidermidis.
and S. haemolyticus ($P<0.05$). However, its inhibitory effect on P. aeruginosa was not obvious and no bacteriostasis ring in the group treated with ZCHO containing 34% terpinen-4-ol was observed. Compared with the treatment of ZCHO containing 34% terpinen-4-ol, the diameter of bacteriostasis ring in the group treated with ZCHO with 79% terpinen-4-ol was larger ($P<0.05$) (Table 3).

The acute toxicity of ZCHO

The mortality of mice was increased due to the increase of ZCHO concentration in experimental groups. Their mortality reached 100% when ZCHO concentration was 40%; however, all mice in the negative control group survived (Tables 4 and 5).

The mice in the groups treated with ZCHO at the dosages of 3732.00, 2929.62 and 2248.53 mg/kg were lethargic, with tachypnea, laryngeal stridor, and decreased vigor. Instability of gait, muscle trembling and ataxia were also observed within 15 min after the administration of ZCHO, and these mice finally became comatose and died. Nearly 33% of mice died within 4 h, while others died within 3 days after the administration of ZCHO. The mice treated with ZCHO at the dosages of 1735.38, 1334.19 and 1026.30 mg/kg showed tachypnea and

| Group | Concentration (%) | Dosage (mg/kg) |
|-------|------------------|----------------|
| Negative control | 0 | 0 |
| A | 40.0 | 3732.00 |
| B | 31.4 | 2929.62 |
| C | 24.1 | 2248.53 |
| D | 18.6 | 1735.38 |
| E | 14.3 | 1334.19 |
| F | 11.0 | 1026.30 |
| G | 8.4 | 783.72 |
| H | 6.5 | 606.45 |

**Table 4.** The distribution of Zingiber corallinum Hance essential oil with various concentrations.

| Group | Dosage (mg/kg) | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
|-------|----------------|------|------|------|------|------|------|------|
| A | 3732.00 | 6 | 3 | 1 | 0 | 0 | 0 |
| B | 2929.62 | 6 | 1 | 0 | 0 | 0 | 0 |
| C | 2248.53 | 5 | 3 | 0 | 0 | 0 | 0 |
| D | 1735.38 | 4 | 1 | 0 | 0 | 0 | 0 |
| E | 1334.19 | 1 | 0 | 0 | 0 | 0 | 0 |
| F | 1026.30 | 2 | 0 | 0 | 0 | 0 | 0 |
| G | 783.72 | 1 | 0 | 0 | 0 | 0 | 0 |
| H | 606.45 | 0 | 0 | 0 | 0 | 0 | 0 |

**Table 5.** The mortality frequency distribution of mice treated with Zingiber corallinum Hance essential oil with various dosages (n=10).

| Group | Dosage (mg/kg) | Mortality time point (h) | Mortality number | Mortality (%) | Survival (%) |
|-------|----------------|--------------------------|------------------|----------------|--------------|
| Negative control | 0 | – | 0 | 0 | 100 |
| A | 3732.00 | 1 | 10 | 100 | 0 |
| B | 2929.62 | 3 | 7 | 70 | 30 |
| C | 2248.53 | 2 | 8 | 80 | 20 |
| D | 1735.38 | 8 | 5 | 50 | 50 |
| E | 1334.19 | 11 | 1 | 10 | 90 |
| F | 1026.30 | 0.5 | 2 | 20 | 80 |
| G | 783.72 | 12 | 1 | 10 | 90 |
| H | 606.45 | – | 0 | 0 | 100 |

**Table 6.** The mortality of mice in acute toxicity test (n=10).
**LD₅₀ and 95% confidence interval**

The LD₅₀ of ZCHO was 1790.427 mg/kg. The 95% confidence interval was between 1629.018 and 1951.836 mg/kg.

**The pathological analysis**

Through histopathological examination, toxicity lesions in mice treated with ZCHO at high dosage of 2248.53 mg/kg were mainly observed in lung, liver, intestine and kidney tissues. The alveolar space of dead mice had obvious pink fluid and hemorrhage. The alignment of hepatocytes exhibited a slight derangement, with fuzziness of the hepatic cord, sporadic punctiform and lamellar necrosis. A large number of intestinal epithelial cells had degeneration and necrosis. The integrity of villi was destroyed (Figure 2); however, no damage to other organs was observed.

**MIC of ZCHO on drug-resistant Acinetobacter baumannii**

Multiple proportion microdilution assays of ZCHO showed that the bacteria fluid in flasks at the concentrations of 10%, 5%, 2.5%, 1.25%, 0.625%, 0.313% and 0.156% was clear, but the bacteria fluid in flasks at the concentration of 0.078% was cloudy. Since the density of ZCHO was 0.933 g/mL, the MIC for drug-resistant A. baumannii was 1457.81 mg/L.

**MBC of ZCHO on drug-resistant Acinetobacter baumannii**

Multiple proportion microdilution assays of ZCHO showed that 10% ZCHO did not result in colony formation. Sporadic colonies less than 3 in number were occasionally observed in the plates with ZCHO at the concentrations of 5%, 2.5%, 1.25%, 0.625%, 0.313% and 0.156%; however, more than 3 colonies were observed in the plates containing ZCHO at the concentration of 0.078%. Therefore, the MBC of ZCHO on drug-resistant A. baumannii was 1457.81 mg/L.

**DISCUSSION**

In the present study, clinical isolates were used to explore the role of ZCHO in inhibiting drug-resistant bacteria, and the acute toxicity of ZCHO was also evaluated in mice. The results revealed that ZCHO had significant bacteriostasis and bactericidal effects with a low toxicity, especially for drug-resistant A. baumannii. Terpinen-4-ol, a major antibacterial component, made a critical contribution to the treatment of infectious diseases, with satisfactory safety due to its excellent antibacterial capability and low toxicity [4].

Currently, although HOI has attracted tremendous attention, and multiple strategies in management and monitoring of HOI have been significantly improved, the incidence of HOI continues to increase year by year [29,30]. According to statistical analysis of clinical isolates from infected patients, 13% of infections were mixed. In addition, among infections from a single bacterium variant, gram-positive and gram-negative infections were 65% and 25%, respectively. Fungi caused 9.5% of infections [31,32]. Increasing evidence also suggests that the infection caused by gram-negative bacteria was the principal factor for morbidity and mortality [33–36]. These bacteria invade the human body through ventilation and surgical equipment, and invasive cannula such as deep vein, intra-urethral and gastric canal. Therefore, HOI incidence reached 9.1% in clinical patients receiving treatments using invasive equipment for chronic or deterioration status [37]. Some patients also suffered from multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF), the leading cause of death in ICUs [38–41]. Since the prophylaxis and treatment of HOI mainly depends on antibiotics, the extensive and irregular use of antibiotics can result in the increase and diffusion of drug-resistant bacteria, which attenuates therapeutic effects of antibiotics [42]. Hence, the screening of novel and effective anti-bacterial drugs to drug-resistant bacteria is one of the most compelling medical research topics. Natural product drugs such as ZCHO, tea tree essential oil and others have gained extensive attention. These drugs have not only demonstrated robust anti-microbial activity, but also exhibited low possibility of drug resistance.

In clinical practice, ZCHO has been extensively used as an antibacterial and antymycotic drug for dermatological diseases including tinea corporis, tinea cruris and beard acne [43]. Previous studies only reported the inhibitory effect of ZCHO on fungi and non-drug resistant bacteria, except for penicillin-fast S. aureus [44]. However, our results indicate that ZCHO exhibits a clear inhibitory effect on both...
gram-negative and gram-positive drug-resistant bacteria such as E. coli, K. pneumoniae, E. cloacae, S. aureus, S. epidermidis and S. haemolyticus. In addition, A. baumannii is widely distributed in water, soil, skin and hospital environmental surfaces as the major pathogenic bacteria in hospital-acquired infections [45]. This multi-drug-resistant staphylococcus may spread throughout an entire city, or between districts and nations. It has also become a dangerous pathogenic bacterium in war wound-related infections. Soldiers infected with A. baumannii have attracted extensive attention in the Iraq and Afghanistan wars [46–48]. Our results also demonstrated that ZCHO played an important role in bacteriostasis and sterilization on multi-drug-resistant A. baumannii.

The possible bacteriostasis and bactericidal mechanisms of ZCHO are described as follows. First, ZCHO may damage the plasma membrane to enhance its permeability. The successful infiltration of ZCHO to microorganisms can result in disruption of organelle and nucleus [49,50]. Second, bacterial enzymatic systems may also be impaired by ZCHO [51]. Third, interaction between ZCHO and plasma membrane can interrupt respiratory chain activity and energy production [52]. The intrinsic resistance of P. aeruginosa may result from the lack of pharmacological targets or failure of binding to active sites [53]; therefore, low sensitivity of ZCHO on P. aeruginosa may be due to its intrinsic resistance. In addition, tea tree essential oil also contains monoterpane alcohol and terpinen-4-ol for executing anti-microbial activity [54].

CONCLUSIONS

ZCHO is a low toxicity drug with obvious bacteriostasis and bactericidal effects, especially for drug-resistant A. baumannii. Terpinen-4-ol is the major antibacterial component of ZCHO. Therefore, ZCHO is a promising natural bioactive drug with satisfactory safety and antibacterial effect, especially for the bacteriostasis on drug-resistant A. baumannii. Moreover, due to technological improvement in the isolation and purification of bioactive components in Chinese herbal medicines, more novel and effective formulations containing ZCHO will be developed, which will further increase the antibacterial capability due to its high purity and low toxicity. Therefore, ZCHO should have promising clinical application value in the future.

Acknowledgments

The authors thank Ms. Li Cai for her technical assistance.

REFERENCES:

1. Davis KA, Stewert JF, Crouch HK et al: Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis, 2004; 39: 776–82
2. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, Paul-Ehrlich-Society for Chemotherapy, Paul-Ehrlich-Society for Chemotherapy: Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001. Int J Antimicrob Agents, 2004; 23: 577–81
3. Hammer KA, Carson CF, Riley TV: Influence of organic matter, cations and surfactants on the antimicrobial activity of Melaleuca alternifolia (tea tree) oil in vitro. J Appl Microbiol, 1999; 86: 446–52
4. Edris AE: Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: a review. Phytother Res, 2007; 21: 308–23
5. Zhang RX, Yu DS: Research and progress in traditional plant Zingiber officinale: Journal of Sichuan of Traditional Chinese Medicine, 2004; 22: 26–28
6. Cao Y, Zhang SY, Zhu RH: Investigation of anti-fungal effects by Vitis Zingiber Corallinum Hance and its Clinical therapeutic effect. Chin J Derm Venereol, 1989; 22: 103–5
7. Nishio H, Komatsu M, Shihata N et al: Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J Clin Microbiol, 2004; 42: 5256–63
8. Chen NN, Cao Y, Li SF: Research on the antibacterial effects of Zingiber Corallinum Hance. Oil and tea tree oil on five type of bacteria. Health professional education, 2007; 25: 102–5
9. Cao Y, Zhang SY, Zhu RH: Ultrastructure Observation of T. Rubrum Affected by 1% Essential Oil of Zingiber Corallinum Hance with TEM. Journal of Guiyang Medical College, 1990; 15: 58–60
10. Yang ZN, Luo SQ, Peng QC et al: GC-MS Analysis of the Essential Oil of Coral Ginger (Zingiber Corallinum Hance) Rehmann Obtained by Supercritical Fluid Extraction and Steam Distillation Extraction. Chromatographia, 2009; 69: 785–90
11. Jiang VP, Cao Y, Li SF: Experimental studies on the inhibitory effects of Zingiber Corallinum Hance essential elements on phytopherospor ova: Journal of Guiyang Chinese Medical College, 2006; 5: 57–59
12. Dent LL, Marshall BR, Pratap S, Hulette RB: Multidrug-resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis, 2010; 10: 196
13. Hamouda A, Vali L, Ames SG: Gram-negative non-fermenting bacte-ria from food-producing animals are low risk for hospital-acquired in-fections. J Chemother, 2008; 20: 702–8
14. Choi WS, Kim SH, Jeon EG, Son MH, Yoon YK, Kim JY et al: Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J Koream Med Sci, 2010; 25: 999–1004
15. Garauacho Montero J, Amaya-Villar R: Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis, 2010; 23: 332–39
16. Ozbek B, Onik G: In vitro activities of tigecycline alone and in combi-nation with colistin sulfate or sulfactam against carbapenem-suscepti-ble and-resistant Acinetobacter baumannii strains isolated from Intensive Care Units. Int J Antimicrob Agents, 2010; 36(2): 191–92
17. Higgins PG, Dammhuyn C, Hackel M, Seifert H: Global spread of car-bapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother, 2010; 65: 233–38
18. Merkier AK, Catalano M, Ramírez MS et al: Polycenal spread of bla(OXA/23) and bla(OXA/38) in Acinetobacter baumannii isolates from Intensive Care Units. Int J Antimicrob Agents, 2010; 36(2): 191–92
19. Martinez AF, Kuchenrucker R, Sukienik T et al: Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme: dissemination in Southern Brazil. Infection, 2009; 37: 474–76
20. Doi Y, Wachino J, Yamane K et al: Spread of novel aminoglycoside resis-tance gene aac(6’)-Icc among Acinetobacter clinical isolates in Japan. Antimicrob Agents Chemother, 2004; 48: 2075–80
21. Ho PL, Ho AV, Chow KH et al: Epidemiology and cloneity of multi-drug-resistant Acinetobacter baumannii from a healthcare region in Hong Kong. J Hosp Infect, 2010; 74: 358-64
22. Jesung OK, Jang SJ, Li XM et al: Prevalence and spread of integron-1886 in inpenem-resistant Acinetobacter baumannii clinical isolates in South Korea. Int J Antimicrob Agents, 2009; 34: 612–14
23. Sneath PHA, NS Mair, ME Sharpe, JG Holt: Bergey’s Manual of Systematic Bacteriology (9 th ed.). Vol. 2. The Williams and Wilkins Co., Baltimore, MD, 1986
24. Williams ST, ME Sharpe, JG Holt: Bergey’s Manual of Systematic Bacteriology (9 th ed.). Vol. 4. The Williams and Wilkins Co., Baltimore, MD, 1989
25. National Committee for Clinical Laboratory Standardis: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobiocically – 6 th Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003
26. Armitage P, Allen I: Methods of estimating the LD 50 in quantal re-sponse data. J Hyg (Lond), 1950; 48: 298–322
27. Barnard DL, Wong MH, Bailey K et al: Effect of oral gavage treatment with ZnAl42 and other metal-los-iron formulations on influenza A H5N1 and H1N1 virus infections in mice. Antivir Chem Chemother 2011; 17: 125–32

28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100S15. CLSI, Wayne, PA, USA, 2005

29. Joseph NM, Sistla S, Dutta TK et al: Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. J Infect Dev Ctries, 2010; 4: 218–25

30. Al Kandari M, Jamal W, Udo EE El Sayed A et al: A case of community-onset meningitis caused by hospital methicillin-resistant Staphylococcus aureus successfully treated with linezolid and rifampicin. Med Prin Pract, 2010; 19: 235–39

31. Markogiannakis H, Pachylaki N, Samara E et al: Infections in a surgical intensive care unit of a university hospital in Greece. Int J Infect Dis, 2009; 13: 145–53

32. Lazarus HM, Fox J, Lloyd JF et al: A six-year descriptive study of hospital-associated infection in trauma patients: demographics, injury features, and infection patterns. Surg Infect (Larchmt), 2007; 8: 463–73

33. Cao Y, Cheng B, Wu CL: Culture and Analysis of Antibacterial Activity of the carboxymethyl-pachymaran. Journal of Guangxi Normal University, 2006; 8: 73–78

34. Burt S: Essential oils: their antibacterial properties and potential applications. Clin Microbiol Rev, 2006; 19: 50–62

35. Osborn TM, Tracy JK, Dunne JR et al: Epidemiology of sepsis in patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep, 2004; 53: 1063–66

36. Centers for Disease Control and Prevention (CDC): Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep, 2004; 53: 1063–66

37. May J, Chan CH, King A et al: Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother, 2000; 45: 639–43

38. Naas T, Levy M, Hirschauer C et al: Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol, 2005; 43: 4826–29

39. Quale J, Bratu S, Landman D, Heddurshetti R: Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis, 2005; 37: 214–20

40. Van Looveren M, Goossens H; ARPAC Steering Group: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect, 2004; 10: 684–704

41. Liu SY, Lin JY, Chu C et al: Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents, 2006; 27: 81–84

42. Carson F, Hammer A, Riley V: Potentiation of methicillin activity by active components in spices. J Food Prot, 1995; 58: 280–83

43. Naas T, Levy M, Hirschauer C et al: Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol, 2005; 43: 4826–29

44. Van Looveren M, Goossens H; ARPAC Steering Group: Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect, 2004; 10: 684–704

45. Rahal JJ, Urban C: Acinetobacter. Semin Respir Crit Care Med, 2000; 21: 341–48

46. Calhoun JH, Murray CK, Mauning MM: Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res, 2008; 466: 1356–62

47. Stuart TL, Mubey M, Simor AE et al: Acinetobacter baumannii in casualties returning from Afghanistan. Can J Infect Control, 2007; 22: 152–54

48. Centers for Disease Control and Prevention (CDC): Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep, 2004; 53: 1063–66

49. May J, Chan CH, King A et al: Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother, 2000; 45: 639–43

50. Burt S: Essential oils: their antibacterial properties and potential applications in foods – a review. Int J Food Microbiol, 2004; 94: 639–43

51. Nicolson K, Evans G, O'Toole PW: Potentiation of methicillin activity by diterpenes. FEMS Immunol Med Microbiol, 2002; 33: 195–99

52. Houang ET, Chu YW, Leung CM et al: Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol, 2001; 39: 228–34

53. Lee K, Ha GY, Shin BM et al: Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) group. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2005: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp. Diagn Microbiol Infect Dis, 2004; 50: 51–58

54. Levin AS, Mendes CM, Sinto SI et al: An outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Sao Paulo, Brazil. Infect Control Hosp Epidemiol, 1996; 17: 366–68

55. Carson F, Hammer A, Riley V: Potentiation of methicillin activity by active components in spices. J Food Prot, 1995; 58: 280–83

56. Nicolson K, Evans G, O'Toole PW: Potentiation of methicillin activity by diterpenes. FEMS Immunol Med Microbiol, 2002; 33: 195–99

57. Osborn TM, Tracy JK, Dunne JR et al: Epidemiology of sepsis in patients with traumatic injury. Crit Care Med, 2004; 32: 2234–40

58. Carson F, Hammer A, Riley V: Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev, 2006; 19: 50–62